Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 541 of 6351
-
New hope for lung cancer patients whose treatment has failed
Disease control Recruiting nowNon-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a monotherapy or in combination with osime…
Phase 2/3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Robot vs. sonographer: 70,000 women join breast cancer screening showdown
Diagnosis Recruiting nowThe goal of this clinical trial is to learn if robotic ultrasound screening works as well as or better than traditional sonographer-led screening for detecting breast cancer. It will also explore how well participants follow recommended post-screening care. The main questions it …
Sponsor: Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC
-
Promising new drug cocktail targets tough pancreatic cancer
Disease control Not yet recruitingThis is a prospective, multicenter, randomized, double-blind, placebo-controlled study. Led by The First Affiliated Hospital with Nanjing Medical University and Peking University Cancer Hospital \& Institute (as leading centers), its main purpose is to evaluate the clinical effic…
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo aims to fight advanced ovarian cancer before surgery
Disease control Recruiting nowA Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer
Phase 1/2 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Extra vaccine dose: could it shield dialysis patients from hepatitis b?
Prevention CompletedPeople with kidney failure who are on dialysis have a weaker immune response to the hepatitis B vaccine than healthy people. Even after vaccination, many dialysis patients do not develop enough protection against hepatitis B infection. Doctors do not agree on whether giving 3 dos…
Sponsor: Jinnah Hospital • Aim: Prevention
Last updated Aug 27, 2026 00:00 UTC
-
Liver cancer trial aims to shrink tumors before surgery with immune booster
Disease control Recruiting nowThis is a single-arm, single-center, prospective trial designed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with ipalimab/tuvonralimab (QL1706) in the peri-operative setting for resectable hepatocellular carcinoma exceeding the Milan cri…
Sponsor: Fudan University • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New cell therapy aims to make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies. Orca-T is an allogeneic stem cell and T-cell immunothe…
Phase 2 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a cancer therapy tame multiple sclerosis? new trial launches
Disease control Recruiting nowThis trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug combo takes on tough lung cancer
Disease control Recruiting nowThis study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body. To join the s…
Phase 2/3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for lung cancer: experimental drug HC010 enters phase 2 trial
Disease control Recruiting nowPhase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS ≥1%)
Phase 2 • Sponsor: HC Biopharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Could a diabetes drug restore ovulation in PCOS? new trial begins
Disease control Recruiting nowThis clinical study examines whether tirzepatide can improve ovarian dysfunction in premenopausal women with polycystic ovary syndrome (PCOS) who are overweight or have obesity. Tirzepatide is already approved for the treatment of diabetes and obesity, but its effects on ovarian …
Phase 4 • Sponsor: University of Bonn • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New combo therapy targets tough pancreatic cancer
Disease control By invitation onlyThis study is a prospective, single-arm trial, aiming to enroll 30 patients with unresectable locally advanced or oligometastatic pancreatic cancer. The study will evaluate the efficacy and safety of nintedanib combined with radiotherapy and chemotherapy (gemcitabine or capecitab…
Phase 2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Glow-in-the-Dark dye could help surgeons remove lung cancer more completely
Diagnosis Recruiting nowThe aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) infusion in patients undergoing VATS (Video-Assisted Thoracoscopic Sur…
Phase 2 • Sponsor: Integro Theranostics • Aim: Diagnosis
Last updated Jun 27, 2026 12:09 UTC
-
New drug aims to boost stroke recovery in major trial
Disease control Recruiting nowThis study is designed to determine the efficacy and safety of SHPL-49 intravenous infusion in acute ischemic stroke patients.
Phase 3 • Sponsor: Shanghai Hutchison Pharmaceuticals Limited • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Liver cancer showdown: which radiation works best?
Disease control Recruiting nowThe proposed study is a single site, prospective, randomized phase 2 study to evaluate the efficacy and tolerability transarterial radioembolization (TARE) versus stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma. The SBRT arm of the trial will involve stand…
Phase 2 • Sponsor: Henry Ford Health System • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New DNA vaccine aims to keep liver cancer at bay after surgery
Disease control Recruiting nowThis is a single-arm, open-label, multi-center Phase 2 clinical study to evaluate the efficacy and safety of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma after curative resection.
Phase 2 • Sponsor: Newish Technology (Beijing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for advanced prostate cancer: drug cocktails enter human trials
Disease control Recruiting nowThis is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.
Phase 2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New pill for duchenne MD enters Mid-Stage trial in young boys
Disease control Recruiting nowPhase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial has two parts. In Part 1, the trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tol…
Phase 2 • Sponsor: Satellos Bioscience, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat lung cancer in veterans
Disease control Recruiting nowThis is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for patients with advanced non-small cell lung cancer who have progressed from front or second-line treatment. Patients will b…
Phase 1/2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for tough lymphoma: drug combo trial launches
Disease control Not yet recruitingTo evaluate the safety of mitoxantrone hydrochloride liposome combined with enlonstobart in the treatment of relapsed or refractory peripheral T-cell lymphoma, to determine the optimal dosage of mitoxantrone hydrochloride liposome within the combination regimen, and to assess the…
Phase 1/2 • Sponsor: Sun Yat-Sen University Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC